Phenotypic and Transcriptomic Description of Megakaryocytes in Sickle Cell Patient

NCT06887907 | Recruiting

• 1 other identifier: RC31/25/0017
• Study Type: observational
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

Sickle cell disease is the most common inherited blood disorder in the world. Chronic hemolysis induces platelet activation and chronic inflammation. Platelets and megakaryocyte, as medullar platelets precursors, are known to play a role in innate immunity. Little is known about the role of megakaryocytes at basal state and during acute complication in sickle cell disease patients. The aim of this study is to evaluate the role of megakaryocytes in sickle cell disease.

Conditions

Sickle Cell Disease (SCD)

Keywords

Megakaryocyte; Sickle Cell Disease

Outcome Measures

Primary Outcomes (1)

• Description of circulant megakaryocytes

  Phenotypic and transcriptomic description of circulant megakaryocytes in sickle cell patient

  12 months

Study Arms (4)

Sickle cell disease patients at rest since at least 1 year

Patient at steady state since at least 1 year

Sickle cell disease patients at rest

Patient at steady state (without crises)

Vaso-occlusive crisis

Sickle cell disease patients during vaso-occlusive crisis

Acute chest syndrome

Sickle cell disease patients during acute chest syndrome

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patient from CHU de Toulouse at steady state since at least 1 year or at steady state (without crisis), or during vaso-occlusive crisis or during acute chest syndrome

You may qualify if:

• Sickle cell disease SS or S-béta° thalassemia
• Patient at steady state since at least 1 year or at steady state (without crisis), or during vaso-occlusive crisis or during acute chest syndrome
• Age \> 18 years old

You may not qualify if:

• Patient objects to take part in the study Hematologic disorder (leukemia, myeloma, myelodysplasic syndrome, myeloproliferative syndrome)
• Immune thrombocytopenia, Immunosuppressive or anti-inflammatory (biotherapies, corticosteroids, non steroidal anti-inflammatories drugs) Page 12 sur 23
• Anti-platelets agents
• Red blood cell exchange or transfusion \< 3 months

Sponsors & Collaborators

• University Hospital, Toulouse: lead

Study Sites (1)

CHU de Toulouse

Toulouse, France, 31059, France

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

Blood sample withdraw from sickle cell disease patients

MeSH Terms

Conditions

Anemia, Sickle Cell

Condition Hierarchy (Ancestors)

Anemia, Hemolytic, Congenital; Anemia, Hemolytic; Anemia; Hematologic Diseases; Hemic and Lymphatic Diseases; Hemoglobinopathies; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Study Officials

• Pierre COUGOUL, MD

  University Hospital, Toulouse

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Pierre COUGOUL, MD

CONTACT

0531156265; cougoul.pierre@iuct-oncopole.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 14, 2025
• First Posted: March 20, 2025
• Study Start: March 13, 2025
• Primary Completion (Estimated): April 1, 2027
• Study Completion (Estimated): April 1, 2028
• Last Updated: March 20, 2025

Record last verified: 2025-03

Locations

FR (1)